The Latest Breaking News from VKTX

Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

With weight-loss drugs gaining traction, which biopharma stock wins?

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…